• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Orion

78.45 EUR-0.82 %24.7, 17.29
14,449 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-0.82 %
+13.86 %
+12.88 %
+11.91 %
+23.25 %
+11.51 %
+123.70 %
+121.30 %
+598.58 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
11.07B EUR
Turnover
12.87M EUR
P/E (adj.) (26e)
19.07
EV/EBIT (adj.) (26e)
14.9
P/B (26e)
6.83
EV/S (26e)
5.23
Dividend yield-% (26e)
2.27 %
Coverage
Recommendation
Accumulate
Target price
83.00 EUR
Updated
19.07.2026
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 20.07.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Good news coming in, as the lower end of the 2026 outlook was raised for both revenue and operating profit: ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2026 July 17, 2026, at 12:00 Orion Group Half-Year Financial Report January–June 2026 April–June 2026 in brief Revenue was ...
7/17/2026, 9:19 AM
by Paapaa
26
Thanks for the great question! The short answer is that I agree regarding the uncertainty/risk in pricing, and it has been accounted for by being conservative in our forecasts. Here is a slightly longer version and a few comments: I would point out here that the highest royalty tier...
7/22/2026, 7:21 AM
by Antti Siltanen
15
Here is Liisa’s interview for a summery Friday. 00:00 Q2 in brief 00:44 Divina 02:10 Easyhaler 02:55 Generic medicines 04:39 Tessie 06:25 LEVEL study 07:55 Net cash position (Net debt-free balance sheet) 09:53 Guidance upgrade I referred to the ROAST a couple of times, here is a ...
7/17/2026, 12:43 PM
by Verneri Pulkkinen
13
These are fantastic numbers and growth. Especially the amount of free cash flow in Q2 is significant.
7/17/2026, 9:28 AM
by Sergio
13
CEO Liisa Hurme: A strong quarter: growth ACCELERATED and profitability improved "In April–June 2026, our net sales grew by 25.2 percent to 521.6 (416.5) million euros, and our operating profit grew by 68.8 percent to 176.6 (104.6) million euros. We have another very strong quarter...
7/17/2026, 10:55 AM
by Dissidentti
10
There are certainly many moving parts here, but generic enzalutamide is no longer just a future possibility. In the EU, Xtandi’s patent protection expires this year, and Enzalutamide Viatris already received marketing authorization in 2024. Meanwhile, in the US, the FDA has approved...
7/21/2026, 1:41 PM
by Juho R
6
Antti’s report provided a good breakdown of where this year’s strong results are coming from. Nubeqa royalties grew by 80%, and the highest royalty tier was reached as early as Q2. However, this brings to mind one question regarding longer-term forecasts. Now that the highest royalty...
7/21/2026, 11:43 AM
by Juho R
6
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.10
2026

Half year dividend

28.10
2026

Interim report Q3'26

17.2
2027

Annual report '26

Orion Q2'26: Engangsmedvind bidrog til topresultatet
Research20.07.2026, 07.00 by
Antti Siltanen

Orion Q2'26: Engangsmedvind bidrog til topresultatet

Omsætningsvækst og en stigning i royaltyprocenten understøttede et stærkt kvartal.

Orion
Orion, Webcast, Q2'26
Webcast17.07.2026, 13.00

Orion, Webcast, Q2'26

Orion
Regulatory press release17.07.2026, 11.00

Orion Group Half-Year Financial Report January–June 2026

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release17.07.2026, 09.30

Orion Corporation’s financial reporting and Annual General Meeting in 2027

Orion
Regulatory press release15.07.2026, 08.00

45,611 Orion Corporation A shares converted into B shares

Orion
Orion Q2'26 preview: Royalties øger resultatet
Analyst Comment13.07.2026, 06.20 by
Antti Siltanen

Orion Q2'26 preview: Royalties øger resultatet

Resultatgevinsten fra Nubeqa-royalties løfter EBIT-marginen til 30,2% i vores Q2-estimat.

Orion
Press release03.07.2026, 08.00

Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026

Orion
Orion indgår aftale om rettigheder til vigtigt biosimilært lægemiddel i Europa
Analyst Comment30.06.2026, 07.55 by
Antti Siltanen

Orion indgår aftale om rettigheder til vigtigt biosimilært lægemiddel i Europa

Rettighederne til en biosimilær version af et kræftlægemiddel til 10 mia. EUR giver vækstpotentiale, men løfter endnu ikke estimaterne.

Orion
Press release30.06.2026, 07.00

Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market

Orion
Orions ODM-212 fik også særstatus som lægemiddel i EU
Analyst Comment24.06.2026, 06.00 by
Antti Siltanen

Orions ODM-212 fik også særstatus som lægemiddel i EU

Særstatus som lægemiddel til sjældne sygdomme giver ODM-212-kandidaten eksklusivitet på markedet i op til 10 år.

Orion
Press release23.06.2026, 08.30

Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

Orion
Regulatory press release18.06.2026, 13.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release17.06.2026, 15.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release16.06.2026, 15.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release15.06.2026, 15.15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release11.06.2026, 16.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release10.06.2026, 17.10

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release05.06.2026, 16.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release01.06.2026, 13.00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Orion: Første resultater fra lægemiddelkandidat ODM-212
Analyst Comment01.06.2026, 07.34 by
Antti Siltanen

Orion: Første resultater fra lægemiddelkandidat ODM-212

Fase I/II-studiet er allerede fortsat til næste del.

Orion